Recent Investment Analysts’ Ratings Changes for GSK (GSK)

GSK (LON: GSK) recently received a number of ratings updates from brokerages and research firms:

  • 9/21/2022 – GSK had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a GBX 1,500 ($18.12) price target on the stock.
  • 9/15/2022 – GSK had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 9/15/2022 – GSK was upgraded by analysts at Credit Suisse Group AG to a “neutral” rating. They now have a GBX 1,430 ($17.28) price target on the stock, down previously from GBX 1,630 ($19.70).
  • 9/14/2022 – GSK had its price target lowered by analysts at Berenberg Bank from GBX 1,950 ($23.56) to GBX 1,580 ($19.09). They now have a “buy” rating on the stock.
  • 9/8/2022 – GSK was given a new GBX 1,475 ($17.82) price target on by analysts at Jefferies Financial Group Inc..
  • 9/7/2022 – GSK had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a GBX 1,500 ($18.12) price target on the stock.
  • 8/31/2022 – GSK had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a GBX 1,750 ($21.15) price target on the stock.
  • 8/31/2022 – GSK was given a new GBX 1,900 ($22.96) price target on by analysts at JPMorgan Chase & Co..
  • 8/25/2022 – GSK had its “not rated” rating reaffirmed by analysts at Shore Capital.
  • 8/25/2022 – GSK was given a new GBX 1,900 ($22.96) price target on by analysts at JPMorgan Chase & Co..
  • 8/16/2022 – GSK had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a GBX 1,750 ($21.15) price target on the stock.
  • 8/12/2022 – GSK had its “not rated” rating reaffirmed by analysts at Shore Capital.
  • 8/3/2022 – GSK had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a GBX 1,750 ($21.15) price target on the stock.
  • 7/28/2022 – GSK was given a new GBX 1,630 ($19.70) price target on by analysts at Credit Suisse Group AG.
  • 7/28/2022 – GSK was given a new GBX 1,850 ($22.35) price target on by analysts at UBS Group AG.
  • 7/27/2022 – GSK had its “not rated” rating reaffirmed by analysts at Shore Capital.
  • 7/26/2022 – GSK had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 1,900 ($22.96) price target on the stock.
  • 7/26/2022 – GSK had its “hold” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They now have a GBX 1,750 ($21.15) price target on the stock.

GSK Trading Up 1.3 %

Shares of LON GSK traded up GBX 16.80 ($0.20) during midday trading on Friday, hitting GBX 1,312.80 ($15.86). The company’s stock had a trading volume of 8,063,083 shares, compared to its average volume of 8,884,718. The business’s 50 day moving average is GBX 1,493.52 and its two-hundred day moving average is GBX 1,639.79. The firm has a market cap of £53.40 billion and a P/E ratio of 1,151.58. GSK plc has a 12-month low of GBX 1,280.92 ($15.48) and a 12-month high of GBX 1,824.40 ($22.04). The company has a current ratio of 1.43, a quick ratio of 0.35 and a debt-to-equity ratio of 97.67.

GSK Increases Dividend

The business also recently announced a dividend, which will be paid on Thursday, October 6th. Shareholders of record on Thursday, August 18th will be given a dividend of GBX 16.25 ($0.20) per share. This represents a yield of 0.93%. The ex-dividend date is Thursday, August 18th. This is a boost from GSK’s previous dividend of $14.00. GSK’s dividend payout ratio (DPR) is 82.24%.

Insider Buying and Selling at GSK

In other GSK news, insider Emma Walmsley sold 148,525 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,763 ($21.30), for a total transaction of £2,618,495.75 ($3,163,962.97). In the last 90 days, insiders have purchased 24 shares of company stock valued at $37,979.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Further Reading

Receive News & Ratings for GSK plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK plc and related companies with MarketBeat.com's FREE daily email newsletter.